This company has been marked as potentially delisted and may not be actively trading. Aquinox Pharmaceuticals (AQXP) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock AQXP vs. ANIP, GPCR, MNKD, EVO, SPRY, DVAX, LQDA, DYN, ETNB, and OCULShould you be buying Aquinox Pharmaceuticals stock or one of its competitors? The main competitors of Aquinox Pharmaceuticals include ANI Pharmaceuticals (ANIP), Structure Therapeutics (GPCR), MannKind (MNKD), Evotec (EVO), ARS Pharmaceuticals (SPRY), Dynavax Technologies (DVAX), Liquidia (LQDA), Dyne Therapeutics (DYN), 89bio (ETNB), and Ocular Therapeutix (OCUL). These companies are all part of the "medical" sector. Aquinox Pharmaceuticals vs. ANI Pharmaceuticals Structure Therapeutics MannKind Evotec ARS Pharmaceuticals Dynavax Technologies Liquidia Dyne Therapeutics 89bio Ocular Therapeutix Aquinox Pharmaceuticals (NASDAQ:AQXP) and ANI Pharmaceuticals (NASDAQ:ANIP) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, dividends, risk, valuation, earnings, community ranking and institutional ownership. Which has more risk & volatility, AQXP or ANIP? Aquinox Pharmaceuticals has a beta of -7.37, meaning that its share price is 837% less volatile than the S&P 500. Comparatively, ANI Pharmaceuticals has a beta of 0.56, meaning that its share price is 44% less volatile than the S&P 500. Is AQXP or ANIP more profitable? Aquinox Pharmaceuticals has a net margin of 0.00% compared to ANI Pharmaceuticals' net margin of -1.28%. ANI Pharmaceuticals' return on equity of 15.87% beat Aquinox Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Aquinox PharmaceuticalsN/A -30.13% -28.08% ANI Pharmaceuticals -1.28%15.87%6.88% Does the media favor AQXP or ANIP? In the previous week, ANI Pharmaceuticals had 9 more articles in the media than Aquinox Pharmaceuticals. MarketBeat recorded 9 mentions for ANI Pharmaceuticals and 0 mentions for Aquinox Pharmaceuticals. ANI Pharmaceuticals' average media sentiment score of 1.02 beat Aquinox Pharmaceuticals' score of 0.00 indicating that ANI Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Aquinox Pharmaceuticals Neutral ANI Pharmaceuticals Positive Which has better earnings and valuation, AQXP or ANIP? ANI Pharmaceuticals has higher revenue and earnings than Aquinox Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAquinox Pharmaceuticals$25M12.29-$31.58MN/AN/AANI Pharmaceuticals$614.38M2.51$18.78M-$1.14-62.12 Does the MarketBeat Community believe in AQXP or ANIP? ANI Pharmaceuticals received 141 more outperform votes than Aquinox Pharmaceuticals when rated by MarketBeat users. However, 71.88% of users gave Aquinox Pharmaceuticals an outperform vote while only 64.14% of users gave ANI Pharmaceuticals an outperform vote. CompanyUnderperformOutperformAquinox PharmaceuticalsOutperform Votes29971.88% Underperform Votes11728.13% ANI PharmaceuticalsOutperform Votes44064.14% Underperform Votes24635.86% Do insiders and institutionals hold more shares of AQXP or ANIP? 71.7% of Aquinox Pharmaceuticals shares are held by institutional investors. Comparatively, 76.1% of ANI Pharmaceuticals shares are held by institutional investors. 4.0% of Aquinox Pharmaceuticals shares are held by insiders. Comparatively, 12.7% of ANI Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Do analysts rate AQXP or ANIP? ANI Pharmaceuticals has a consensus target price of $80.13, indicating a potential upside of 13.14%. Given ANI Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe ANI Pharmaceuticals is more favorable than Aquinox Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aquinox Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00ANI Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00 SummaryANI Pharmaceuticals beats Aquinox Pharmaceuticals on 14 of the 17 factors compared between the two stocks. Get Aquinox Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AQXP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AQXP vs. The Competition Export to ExcelMetricAquinox PharmaceuticalsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$307.20M$6.60B$5.44B$7.89BDividend YieldN/A2.97%5.37%4.22%P/E RatioN/A7.2024.8818.78Price / Sales12.29242.55388.51105.13Price / CashN/A65.8538.1834.62Price / Book4.226.286.704.25Net Income-$31.58M$143.59M$3.22B$247.93M Aquinox Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AQXPAquinox PharmaceuticalsN/A$13.05-13.6%N/A-53.9%$307.20M$25M0.008High Trading VolumeANIPANI Pharmaceuticals4.4935 of 5 stars$72.56-0.5%$80.13+10.4%+4.3%$1.58B$614.38M-131.93600Upcoming EarningsHigh Trading VolumeGPCRStructure Therapeutics2.3457 of 5 stars$27.55+1.7%$78.63+185.4%-36.3%$1.58BN/A-37.23136Upcoming EarningsPositive NewsMNKDMannKind3.0432 of 5 stars$4.96-0.8%$9.56+92.8%+8.6%$1.51B$285.50M70.86400Upcoming EarningsPositive NewsEVOEvotec1.8521 of 5 stars$4.17-2.8%$5.93+42.3%-22.1%$1.48B$796.97M0.004,200News CoverageSPRYARS Pharmaceuticals3.029 of 5 stars$14.26-1.4%$31.00+117.4%+48.4%$1.40B$89.15M-27.9690Upcoming EarningsDVAXDynavax Technologies4.254 of 5 stars$11.26-0.6%$20.50+82.1%-6.1%$1.38B$277.25M62.56350Earnings ReportAnalyst DowngradeNews CoverageGap DownLQDALiquidia2.7947 of 5 stars$16.12+1.8%$26.88+66.7%+22.7%$1.38B$14.00M-9.8950Upcoming EarningsAnalyst ForecastPositive NewsDYNDyne Therapeutics3.3679 of 5 stars$11.83-0.3%$47.46+301.2%-61.6%$1.34BN/A-3.32100Positive NewsETNB89bio2.9803 of 5 stars$8.61-1.4%$27.25+216.5%-19.2%$1.26BN/A-2.9640Earnings ReportUpcoming EarningsNews CoveragePositive NewsGap UpOCULOcular Therapeutix3.3784 of 5 stars$7.73-12.2%$16.38+111.8%+23.8%$1.23B$63.72M-5.86230Analyst ForecastAnalyst RevisionNews CoverageGap DownHigh Trading Volume Related Companies and Tools Related Companies ANIP Competitors GPCR Competitors MNKD Competitors EVO Competitors SPRY Competitors DVAX Competitors LQDA Competitors DYN Competitors ETNB Competitors OCUL Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AQXP) was last updated on 5/7/2025 by MarketBeat.com Staff From Our PartnersElon Warns “America Is Broke”. Trump’s Plan Inside.Elon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredMost traders are panicking. We’re cashing inMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredVirtually Limitless Energy?A radical energy breakthrough could change everything. Scientists at MIT and a stealth startup may have discov...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aquinox Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Aquinox Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AQXP Stock Free AQXP Stock Alerts